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e-mail address: VLM7@msn.com (V.M. Knudsen).Victoria Morrison Knudsen, M.D. a,⇑; Igor Kozak, M.D., PhD bAbstractPurpose: To evaluate success with intravitreal injection of ocriplasmin in releasing symptomatic vitreomacular traction (VMT).
Methods: A retrospective review of consecutive series of patients in a single vitreoretinal practice. Patients with symptomatic
distortion and loss of vision secondary to VMT were included in the study. Patients received a single injection of ocriplasmin
(JETREA) and were followed-up after 1 month with optical coherence tomography.
Results: Eight patients (8 eyes) were included (2 males and 6 females) in the study. Five of 8 eyes (62.5%) experienced complete
release of the VMT; one of 8 eyes (12.5%) had partial release of VMT and two of 8 eyes (25%) did not have release of VMT. The two
patients with no release of their VMT had the same vision. Of the 5 patients with complete release of VMT, 3 patients had a one
line worsening of their vision, 1 had a 4 line improvement of vision, and 1 stayed the same. The patient with only partial release of
their VMT had a 1 line worsening of vision.
Conclusions: Intravitreal ocriplasmin is a promising treatment option for vitreomacular traction syndrome in symptomatic patients.
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With improvement of vitreoretinal imaging devices over
the past two decades, the ability to diagnose vitreomacular
traction (VMT) has significantly increased. VMT can be a sight
threatening condition, with patients reporting onset of meta-
morphopsia and loss of vision.
As the eye ages, the vitreous gel liquefies and contracts
away from its posterior connections at the retina, optic disk,
and retinal vessels. This process is called a posterior vitreous
detachment (PVD). Posterior vitreous detachment is
detected in half of subjects at 50 years of age and almost
all of the subjects at 80 years of age or older.1
VMT occurs when the vitreous body begins to liquefy and
does not fully release or separate from its collagen fibril
attachments to its central posterior interface, the macula.
The clinical need to treat symptomatic VMT is an importantaspect to the retina specialist’s practice, as VMT is not only
visually significant, but is also thought to be associated with
other pathologic conditions of the eye such as exudative
age related macular degeneration, epiretinal membrane,
macular edema, and retinal vein occlusions.1–3 Treatment of
VMT involves addressing this protein fibril attachment to
the macula.4
Until recently retina specialists had only two options,
observation to see if the fibrils would release spontaneously
over time, or trans pars plana vitrectomy (TPPV) surgery,
where mechanical release of the fibrils would be addressed.
Observation has the risk of ongoing stress to the macular
cells as they remain distorted while the chance of spontane-
ous release is low. Surgery to mechanically release the VMT
with TPPV has the associated risks of infection, hemorrhage,
retinal detachment, increased intraocular pressure, and cata-
ract formation.5,6e:
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cally cleave these protein attachments led to the develop-
ment and recent release of ocriplasmin (JETREA) in
October of 2012. Ocriplasmin is a truncated form of the
human serine protease plasmin and has proteolytic activity
against fibronectin and laminin, two major components of
the vitreoretinal interface.7
Phase 3 multicenter, randomized, double-blind, trials with
single intravitreal injection of ocriplasmin (125 ug) versus a
placebo injection in patients with symptomatic vitreomacular
adhesion results showed resolution of macular adhesion
occurring in 26.5% of ocriplasmin-injected eyes versus
10.1% of placebo-injected eyes (p < 0.001). Nonsurgical clo-
sure of macular holes was achieved in 40.6% of ocriplasmin-
injected eyes, as compared with 10.6% of placebo injected
eyes (p < 0.0001). The best-corrected visual acuity was more
likely to improve by a gain of at least three lines on the eye
chart with ocriplasmin than with placebo. Ocular adverse
events (e.g., vitreous floater, photopsia, or injection-related
eye pain or conjunctival hemorrhage) occurred in 68.4% of
ocriplasmin injected eyes and in 53.5% of placebo injected
eyes (p < 0.001). Thus, intravitreal injection of the vitreolytic
agent ocriplasmin resolved vitreomacular traction and closed
macular holes in significantly more patients than did injection
of placebo but was associated with a higher incidence of ocu-
lar adverse events, which were mainly transient.7
This article is a retrospective review of the success with
ocriplasmin in a consecutive series of patients in a single ret-
ina practice.
Methods
A retrospective review of a single, large physician group
vitreoretinal only practices (including 5 physicians) interven-
tional study using ocriplasmin (JETREA) for the treatmentFigure 1. Patient one with symptomaticof symptomatic VMT. Patients who presented with symptom-
atic distortion and loss of vision secondary to VMT were in-
cluded in the study. Vision was measured with the use of a
Snellen Eye Chart. All patients were checked at their one
month follow-up for the release of the VMT. The VMT was
diagnosed using the Spectral Domain OCT Heidelberg (Hei-
delberg Engineering, Carlsbad, CA). Following informed
consent a single injection of JETREA 125 ug was adminis-
tered under sterile technique (povidone iodine, lid speculum
placement, etc.) as previously published.8 The injection was
performed 3.5–4.0 mm pars plana, and the patient was con-
firmed to have count fingers vision or better immediately
after the injection. The patients presented with initial diagno-
sis of visually significant VMT. Patients with a history of anti-
VEGF treatment, wet macular degeneration, diabetic reti-
nopathy or macular hole were excluded. Patients without at
least a one month follow-up were excluded.
Results
Eight patients (8 eyes) were included (2 males and 6
females). Four of the eyes involved the right eye and 4 eyes
were the left eye. There were no patients with bilateral
involvement. The average age of patients was 76.6 years.
62.5% of patients (5/8 eyes) experienced complete release
of the VMT. 12.5% of patients (1/8 eyes) experienced partial
release of VMT. 25% of patients (2/8 eyes) did not have re-
lease of VMT. The two patients who did not experience re-
lease of their VMT had the same vision in one eye and the
other patient experienced two lines worsening of vision at
their one month follow-up. Of the 5 patients with complete
release of VMT, 3 patients had a one line worsening of their
vision, 1 had a 4 line improvement of vision, and 1 stayed the
same. The patient with only partial release of their VMT had a
1 line worsening of vision (Figs. 1–6).VMT at time of ocriplasmin injection.
Figure 2. Patient one, 5 weeks following ocriplasmin injection, showing complete release of VMT.
Figure 3. Patient two with visually significant VMT at time of ocriplasmin injection.
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Figure 4. Patient 2, one month after ocriplasmin injection showing only partial release of VMT.
Figure 5. Patient 3 at time of ocriplasmin injection for VMT.
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Figure 6. Patient 3 one month following ocriplasmin injection showing complete release of VMT.
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Ocriplasmin (JETREA) is a clinically significant effective
drug for the retina specialist’s armamentarium for the treat-
ment of visually significant VMT. Although ocriplasmin was
associated with resolution of VMT in just over one-quarter
of patients in the pivotal trials, the improvement in visual acu-
ity was modest.9,10
Safety data of the MIVI-TRUST (Microplasmin for Vitreous
Injection (MIVI), Traction Release Without Surgical Treatment
(TRUST)) showed that the majority of adverse events after
injection were generally mild and occurred in the first week
after treatment with the most commonly reported events
including vitreous floaters, eye pain, photopsia, blurred vi-
sion, and decreased vision.11 Some of our patients experi-
enced initial decrease in vision as a result of VMT release.
The rate was comparable to data from the published clinical
trial.7 Our study did note a success rate of 62.5% with vision
improvement in only one patient at the one month follow-up
point. However, the anatomic success was higher than seen
in other phase 3 trials. Regarding therapeutic effect and
pharmacokinetics, a recent study showed that active ocriplas-
min concentrations in vitreous samples decrease with increas-
ing time from injection, with enzyme levels in the day 7 being
comparable to the control group.12 Therefore, the most
effect is to be expected the first week after ocriplasmin
administration.
Limitations of our study include the small patient number
and the retrospective nature of the study. Also, while
JETREA may have been offered to other patients who
presented with VMT, insurance approval may have limited
our ability to use it in all cases. Financial consideration withthe cost of the drug versus the benefit is also a discussion
we have with our patients, particularly given the fact that
the success rate is limited. These are additional sources of
bias inherent to this type of treatment.
In summary, we believe that ocriplasmin is a promising
treatment option for vitreomacular traction syndrome symp-
tomatic patients.Conflict of interest
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